Latest News and Press Releases

WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway Combined proceeds are...

Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...

Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017   Management to host conference call today at...

WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...

Treatment with selective orexin-2 receptor antagonist observed to be well tolerated and to improve symptoms of depression, independent from its effect on sleep WALTHAM, Mass., March 11, 2016 ...